📗 Cite This Artifact
Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP
Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP
Introduction
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>16S rRNA Sequencing</td>
</tr>
<tr>
<td class="label">Target</td>
<td>V1-V9 variable regions</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>$150-400</td>
</tr>
<tr>
<td class="label">Turnaround</td>
<td>2-4 weeks</td>
</tr>
<tr>
<td class="label">Resolution</td>
<td>Genus/species level</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Cannot distinguish strains</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Shotgun Metagenomics</td>
</tr>
<tr>
<td class="label">Target</td>
<td>All microbial DNA</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>$400-1000</td>
</tr>
<tr>
<td class="label">Turnaround</td>
<td>3-6 weeks</td>
</tr>
<tr>
<td class="label">Resolution</td>
<td>Strain level</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Complex data analysis</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Thryve</td>
<td>16S + metaproteomics</td>
</tr>
<tr>
<td class="label">Viome</td>
<td>Metatranscriptomics</td>
</tr>
<tr>
<td class="label">Microbiome Health</td>
<td>16S + met
Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP
Introduction
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>16S rRNA Sequencing</td>
</tr>
<tr>
<td class="label">Target</td>
<td>V1-V9 variable regions</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>$150-400</td>
</tr>
<tr>
<td class="label">Turnaround</td>
<td>2-4 weeks</td>
</tr>
<tr>
<td class="label">Resolution</td>
<td>Genus/species level</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Cannot distinguish strains</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Shotgun Metagenomics</td>
</tr>
<tr>
<td class="label">Target</td>
<td>All microbial DNA</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>$400-1000</td>
</tr>
<tr>
<td class="label">Turnaround</td>
<td>3-6 weeks</td>
</tr>
<tr>
<td class="label">Resolution</td>
<td>Strain level</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Complex data analysis</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Thryve</td>
<td>16S + metaproteomics</td>
</tr>
<tr>
<td class="label">Viome</td>
<td>Metatranscriptomics</td>
</tr>
<tr>
<td class="label">Microbiome Health</td>
<td>16S + metabolomics</td>
</tr>
<tr>
<td class="label">Zoe</td>
<td>Metagenomics + ML</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Genova Diagnostics</td>
<td>16S + culture</td>
</tr>
<tr>
<td class="label">Doctor's Data</td>
<td>16S + SCFA</td>
</tr>
<tr>
<td class="label">MapMyMicrobiome</td>
<td>Shotgun</td>
</tr>
<tr>
<td class="label">Cosmos ID</td>
<td>qPCR + sequencing</td>
</tr>
<tr>
<td class="label">Metric</td>
<td>Healthy Range</td>
</tr>
<tr>
<td class="label">Shannon Index</td>
<td>3.5-5.0</td>
</tr>
<tr>
<td class="label">Observed ASVs</td>
<td>150-400</td>
</tr>
<tr>
<td class="label">Chao1</td>
<td>200-500</td>
</tr>
<tr>
<td class="label">Taxonomic Group</td>
<td>Healthy Level</td>
</tr>
<tr>
<td class="label">Akkermansia muciniphila</td>
<td>>5% of microbiota</td>
</tr>
<tr>
<td class="label">Bifidobacterium</td>
<td>2-10%</td>
</tr>
<tr>
<td class="label">Lactobacillus</td>
<td>1-5%</td>
</tr>
<tr>
<td class="label">Faecalibacterium</td>
<td>5-15%</td>
</tr>
<tr>
<td class="label">Prevotella</td>
<td>10-30%</td>
</tr>
<tr>
<td class="label">Roseburia</td>
<td>2-8%</td>
</tr>
<tr>
<td class="label">Strain</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">L. plantarum 299v</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">L. reuteri DSM 17938</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">L. rhamnosus GG</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">L. bulgaricus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">L. acidophilus NCFM</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Strain</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">B. longum 1714</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">B. breve 1205</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">B. infantis 35624</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">B. lactis HN019</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">B. bifidum MIMBb75</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Optimal dose</td>
<td>10^8 - 10^10 viable cells</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Live or pasteurized (pasteurized still effective)</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Strong for barrier integrity, metabolic health</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Excellent safety profile</td>
</tr>
<tr>
<td class="label">Note</td>
<td>Requires prebiotic substrate (polyphenols)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 8-12 weeks for assessment</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals (30 min before or with food)</td>
</tr>
<tr>
<td class="label">Storage</td>
<td>Refrigerate; most require cool storage</td>
</tr>
<tr>
<td class="label">Loading dose</td>
<td>First 2 weeks: double dose</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>Standard dose thereafter</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Probiotic Interaction</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Antidepressants (SSRIs)</td>
<td>May enhance effect</td>
</tr>
<tr>
<td class="label">Antibiotics</td>
<td>Probiotics contraindicated</td>
</tr>
<tr>
<td class="label">Proton pump inhibitors</td>
<td>Probiotics still effective</td>
</tr>
<tr>
<td class="label">Anticholinergics</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Study</td>
</tr>
<tr>
<td class="label">Reduced alpha diversity in PSP</td>
<td>Barone et al., 2020</td>
</tr>
<tr>
<td class="label">Decreased Faecalibacterium</td>
<td>Houser et al., 2022</td>
</tr>
<tr>
<td class="label">Altered Firmicutes/Bacteroidetes</td>
<td>Tan et al., 2021</td>
</tr>
<tr>
<td class="label">Increased pro-inflammatory taxa</td>
<td>Bedarf et al., 2017</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Study</td>
</tr>
<tr>
<td class="label">Probiotics improve cognition in AD</td>
<td>Akbari et al., 2016</td>
</tr>
<tr>
<td class="label">L. plantarum reduces inflammation</td>
<td>Moya-Perez et al., 2017</td>
</tr>
<tr>
<td class="label">B. longum reduces stress response</td>
<td>Allen et al., 2016</td>
</tr>
<tr>
<td class="label">Multi-strain probiotic in PD</td>
<td>Tortelli et al., 2020</td>
</tr>
<tr>
<td class="label">Akkermansia improves barrier</td>
<td>Depommier et al., 2019</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Cost Range</td>
</tr>
<tr>
<td class="label">16S sequencing</td>
<td>$150-400</td>
</tr>
<tr>
<td class="label">Shotgun metagenomics</td>
<td>$400-1000</td>
</tr>
<tr>
<td class="label">Metabolomics</td>
<td>$300-800</td>
</tr>
<tr>
<td class="label">Full service (comprehensive)</td>
<td>$500-1500</td>
</tr>
<tr>
<td class="label">Product Type</td>
<td>Monthly Cost</td>
</tr>
<tr>
<td class="label">Consumer probiotics</td>
<td>$20-50</td>
</tr>
<tr>
<td class="label">Professional brands</td>
<td>$30-80</td>
</tr>
<tr>
<td class="label">Custom formulations</td>
<td>$50-150</td>
</tr>
<tr>
<td class="label">Therapeutic dose (medical)</td>
<td>$80-200</td>
</tr>
</table>
The gut microbiome has emerged as a critical modifiable factor in neurodegenerative diseases, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). While Section 101 detailed the mechanistic links between gut dysbiosis and tauopathy pathogenesis, and Section 123 covered intervention strategies, this section focuses on the diagnostic and personalized therapeutic approach—microbiome sequencing and targeted probiotic supplementation.
Personalized probiotic recommendations based on individual microbiome profiles represent a paradigm shift from generic supplementation to precision nutrition. By understanding a patient's specific microbial community structure, practitioners can recommend targeted interventions that address identified deficiencies and restore microbial balance. This approach is particularly relevant for CBS/PSP patients, where gut dysfunction may contribute to neuroinflammation and disease progression.
1. Microbiome Testing Methods
1.1 Overview of Sequencing Technologies
1.2 16S rRNA Gene Sequencing
16S rRNA sequencing targets the conserved 16S ribosomal RNA gene found in all bacteria, allowing identification of bacterial communities at genus and sometimes species level[@hamady2009].
Best for:
- Initial microbiome screening
- Diversity and composition analysis
- Comparing to reference populations
- Tracking changes over time
1.3 Shotgun Metagenomic Sequencing
Shotgun metagenomics sequences all DNA fragments in a sample, providing strain-level resolution and functional gene profiling[@quince2017].
Best for:
- Detailed strain-level analysis
- Functional pathway assessment
- Antimicrobial resistance gene detection
- Research applications
1.4 Complementary Testing Approaches
Metatranscriptomics:
- Measures active gene expression
- Reveals functional activity (not just presence)
- Cost: $500-1500
- Useful for understanding active metabolic pathways
- Profiles microbial metabolites directly
- SCFAs, bile acids, neurotransmitters
- Cost: $300-800
- Validates functional output of microbiome
2. Available Testing Services
2.1 Consumer-Directed Testing
2.2 Clinical-Grade Testing
2.3 Specialized Neuroscience Focus
Several testing services have emerged specifically targeting the gut-brain axis:
Recommended for CBS/PSP:
- Thryve Inside — Provides strain-specific probiotic recommendations based on microbiome profile, with formulations targeting neurological health
- Viome Brain Health — AI analysis specifically trained on gut-brain connection data
- Zoe PREDICT — Personalized nutrition based on gut microbiome and postprandial responses
3. Interpreting Microbiome Results
3.1 Key Metrics for CBS/PSP
3.2 Alpha Diversity
Alpha diversity measures within-sample diversity:
CBS/PSP findings: Studies indicate reduced alpha diversity in PSP patients, correlating with disease severity and motor impairment[@barone2020].
3.3 Taxonomic Markers
Bacterial groups of particular interest in CBS/PSP:
3.4 Functional Indicators
Short-chain fatty acid (SCFA) production:
- Butyrate: >10% of total SCFAs (optimal)
- Propionate: 10-20%
- Acetate: 50-70%
4. Personalized Probiotic Recommendations
4.1 Strain-Specific Benefits
4.2 Lactobacillus Species
Key strains for CBS/PSP:
CBS/PSP-specific recommendations:
- For reduced diversity: L. plantarum 299v
- For mood/cognitive symptoms: L. reuteri
- For barrier dysfunction: L. rhamnosus GG
4.3 Bifidobacterium Species
Key strains for CBS/PSP:
CBS/PSP-specific recommendations:
- For neuroinflammation: B. infantis 35624
- For cognitive/mood: B. longum 1714
- For immune support: B. lactis HN019
4.4 Akkermansia muciniphila
A. muciniphila is a mucin-degrading bacterium with particularly strong evidence for gut-brain axis benefits[@depommier2019]:
CBS/PSP relevance:
- Restores gut barrier integrity
- Reduces endotoxemia
- Anti-inflammatory effects
- May reduce alpha-synuclein propagation
4.5 Combination Formulations
Recommended combinations for CBS/PSP:
Basic formulation:
- L. plantarum 299v — 10 billion CFU
- B. longum 1714 — 2 billion CFU
- L. rhamnosus GG — 10 billion CFU
- A. muciniphila — 5 billion CFU
- B. infantis 35624 — 1 billion CFU
- L. reuteri DSM 17938 — 5 billion CFU
- B. breve 1205 — 10 billion CFU
- L. acidophilus NCFM — 10 billion CFU
- B. lactis HN019 — 10 billion CFU
5. Clinical Implementation
5.1 Assessment Protocol
5.2 Patient Selection
Ideal candidates for microbiome-guided probiotic therapy:
Relative contraindications:
- Active gastrointestinal infection
- Severe immunocompromise
- Recent antibiotic exposure (wait 4 weeks)
- Active inflammatory bowel disease
5.3 Dosing and Administration
Monitoring parameters:
- Bowel habit changes
- bloating/gas (expect temporary increase)
- Cognitive/mood changes
- Inflammatory markers (optional)
5.4 Integration with Existing Treatments
Coordination with standard CBS/PSP therapies:
6. Evidence Base
6.1 Microbiome Alterations in Tauopathies
6.2 Probiotic Evidence in Neurodegeneration
6.3 Specific CBS/PSP Evidence
Direct evidence in CBS/PSP remains limited, with most data extrapolated from:
- Parkinson's disease studies (similar alpha-synuclein pathology)
- Alzheimer's disease studies (similar tau pathology)
- General neurodegeneration studies
- NCT06033890: Urolithin A and microbiome modulation in PSP
- NCT05864297: Probiotic supplementation in PSP (recruiting)
7. Costs and Practical Considerations
7.1 Testing Costs
7.2 Probiotic Costs
7.3 Total Investment
Estimated annual cost for microbiome-guided probiotic therapy:
- Initial testing: $300-1000 (one-time)
- Probiotic supplements: $600-2400
- Follow-up testing (optional): $300-800
- Total: $900-4200/year
8. Decision Framework
8.1 Recommendations by Resource Level
Full protocol (ideal):
Limited resources:
No resources for testing:
9. Summary and Recommendations
9.1 Key Takeaways
9.2 Clinical Algorithm
Recommended approach for CBS/PSP patients:
9.3 Future Directions
The field of microbiome-guided precision probiotics is rapidly evolving:
- Strain-specific databases — Growing evidence for individual strain effects
- Machine learning integration — AI models for optimal formulation selection
- Combination approaches — Synergistic multi-strain/multi-species formulations
- Functional validation — Metabolomics to confirm mechanism
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-section-159-microbiome-sequencing-personalized-probiotics-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-7f1f9c83757e |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-159-microbiome-sequencing-personalized-probiotics-cbs-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-section-159-microbiome-sequencing-personalized-probiotics-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-section-159-microbiome-sequencing-personalized-probiotics-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-section-159-microbiome-sequencing-personalized-probiotics-cbs-psp